Share Price and Basic Stock Data
Last Updated: December 13, 2025, 3:31 am
| PEG Ratio | 2.50 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Global Health Ltd, operating in the Non-Banking Financial Company (NBFC) sector, has demonstrated a commendable growth trajectory in revenue over the past few years. The company reported sales of ₹2,710 Cr in FY 2023, a significant rise from ₹2,167 Cr in FY 2022. This upward trend continued into FY 2024, with sales reaching ₹3,275 Cr. The most recent quarter, June 2025, saw revenues climb to ₹1,031 Cr, indicating an ongoing robust demand for its services. This sequential growth reflects a consistent quarterly performance, with sales increasing from ₹707 Cr in March 2023 to ₹844 Cr in September 2023. Such results signal not only resilience but also an expanding market presence, suggesting that Global Health is capitalizing on favorable economic conditions and effective operational strategies.
Profitability and Efficiency Metrics
Profitability metrics for Global Health Ltd appear strong, with a net profit of ₹534 Cr recorded in the trailing twelve months (TTM). This figure represents a notable increase compared to ₹481 Cr in FY 2025, indicating effective cost management and operational efficiency. The company’s operating profit margin (OPM) stood at 24%, reflecting a stable performance relative to industry peers. Additionally, the return on equity (ROE) at 16.5% and return on capital employed (ROCE) at 19.7% highlight the company’s ability to generate value for its shareholders. However, while these figures are impressive, the price-to-earnings (P/E) ratio of 51.9 may suggest that the stock is priced for perfection, posing a potential risk if growth expectations are not met.
Balance Sheet Strength and Financial Ratios
The balance sheet of Global Health Ltd exhibits a solid foundation, with total assets reported at ₹4,766 Cr and total borrowings at ₹945 Cr. This results in a low debt-to-equity ratio of just 0.09, indicating a conservative approach to leverage, which is a positive sign for risk-averse investors. The company’s current ratio is a healthy 2.48, suggesting it has ample liquidity to cover short-term obligations. However, the price-to-book value (P/BV) ratio of 9.50 times could be seen as stretched when compared to industry averages, which may raise concerns regarding overvaluation. Furthermore, the interest coverage ratio of 14.65 times indicates that the company comfortably meets its interest obligations, further reinforcing its financial stability.
Shareholding Pattern and Investor Confidence
Investor confidence in Global Health Ltd is reflected in its shareholding pattern. Promoters hold a steady 33.01% stake, which has seen minimal fluctuation, suggesting stability in management control and commitment to the company’s long-term vision. Foreign Institutional Investors (FIIs) and Domestic Institutional Investors (DIIs) have also increased their stakes to 11.41% and 12.97%, respectively, indicating growing institutional interest. Meanwhile, public shareholding stands at 42.56%, which is a healthy sign of retail participation. However, the gradual decline in promoter shareholding over time—from 33.08% in December 2022 to the current level—might raise questions about the promoters’ confidence in future prospects, a factor that potential investors should consider.
Outlook, Risks, and Final Insight
Looking ahead, Global Health Ltd’s growth trajectory appears promising, but several risks lurk beneath the surface. The high P/E ratio suggests that expectations are lofty, and any deviation from projected growth could lead to significant corrections in stock price. Additionally, while the company has maintained robust profit margins and efficiency, external economic factors such as interest rate fluctuations and regulatory changes in the NBFC sector could impact profitability. Investors should weigh these risks against the company’s solid operational metrics and strong balance sheet. Overall, while Global Health Ltd shows potential for continued growth, a cautious approach is warranted, focusing on how effectively it can navigate industry challenges and sustain its upward momentum.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Minolta Finance Ltd | 12.7 Cr. | 1.27 | 1.91/1.00 | 1.07 | 0.00 % | 0.40 % | 0.09 % | 1.00 | |
| Money Masters Leasing & Finance Ltd | 8.73 Cr. | 0.87 | 9.18/0.85 | 25.7 | 1.57 | 0.00 % | 4.42 % | 3.94 % | 1.00 |
| Moneyboxx Finance Ltd | 445 Cr. | 136 | 269/126 | 80.1 | 0.00 % | 8.65 % | 0.58 % | 10.0 | |
| Moongipa Capital Finance Ltd | 15.4 Cr. | 16.8 | 34.4/15.0 | 11.5 | 26.6 | 0.00 % | 12.1 % | 9.43 % | 10.0 |
| Morarka Finance Ltd | 38.6 Cr. | 85.8 | 165/74.8 | 20.7 | 238 | 1.16 % | 2.46 % | 2.17 % | 10.0 |
| Industry Average | 29,085.66 Cr | 460.41 | 50.11 | 522.84 | 0.22% | 15.80% | 8.84% | 8.50 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 617 | 679 | 694 | 707 | 780 | 844 | 836 | 809 | 861 | 957 | 943 | 931 | 1,031 |
| Expenses | 485 | 522 | 534 | 540 | 595 | 631 | 620 | 629 | 675 | 728 | 706 | 707 | 784 |
| Operating Profit | 133 | 157 | 160 | 167 | 184 | 213 | 216 | 179 | 186 | 228 | 238 | 225 | 247 |
| OPM % | 21% | 23% | 23% | 24% | 24% | 25% | 26% | 22% | 22% | 24% | 25% | 24% | 24% |
| Other Income | 9 | 16 | 12 | 25 | 15 | 21 | 18 | 27 | 22 | 18 | 16 | -27 | 20 |
| Interest | 19 | 18 | 21 | 20 | 18 | 20 | 18 | 18 | 18 | 16 | 16 | 15 | 14 |
| Depreciation | 36 | 37 | 39 | 38 | 40 | 43 | 44 | 45 | 47 | 49 | 48 | 49 | 45 |
| Profit before tax | 87 | 117 | 112 | 133 | 141 | 171 | 172 | 143 | 144 | 181 | 189 | 133 | 208 |
| Tax % | 33% | 27% | 28% | 24% | 28% | 27% | 28% | 11% | 26% | 28% | 24% | 24% | 24% |
| Net Profit | 59 | 86 | 81 | 101 | 102 | 125 | 124 | 127 | 106 | 131 | 143 | 101 | 159 |
| EPS in Rs | 2.32 | 3.38 | 3.01 | 3.77 | 3.80 | 4.66 | 4.61 | 4.74 | 3.96 | 4.87 | 5.32 | 3.78 | 5.92 |
Last Updated: August 19, 2025, 2:37 pm
Below is a detailed analysis of the quarterly data for Global Health Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 1,031.00 Cr.. The value appears strong and on an upward trend. It has increased from 931.00 Cr. (Mar 2025) to 1,031.00 Cr., marking an increase of 100.00 Cr..
- For Expenses, as of Jun 2025, the value is 784.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 707.00 Cr. (Mar 2025) to 784.00 Cr., marking an increase of 77.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 247.00 Cr.. The value appears strong and on an upward trend. It has increased from 225.00 Cr. (Mar 2025) to 247.00 Cr., marking an increase of 22.00 Cr..
- For OPM %, as of Jun 2025, the value is 24.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 24.00%.
- For Other Income, as of Jun 2025, the value is 20.00 Cr.. The value appears strong and on an upward trend. It has increased from -27.00 Cr. (Mar 2025) to 20.00 Cr., marking an increase of 47.00 Cr..
- For Interest, as of Jun 2025, the value is 14.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 15.00 Cr. (Mar 2025) to 14.00 Cr., marking a decrease of 1.00 Cr..
- For Depreciation, as of Jun 2025, the value is 45.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 49.00 Cr. (Mar 2025) to 45.00 Cr., marking a decrease of 4.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 208.00 Cr.. The value appears strong and on an upward trend. It has increased from 133.00 Cr. (Mar 2025) to 208.00 Cr., marking an increase of 75.00 Cr..
- For Tax %, as of Jun 2025, the value is 24.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 24.00%.
- For Net Profit, as of Jun 2025, the value is 159.00 Cr.. The value appears strong and on an upward trend. It has increased from 101.00 Cr. (Mar 2025) to 159.00 Cr., marking an increase of 58.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 5.92. The value appears strong and on an upward trend. It has increased from 3.78 (Mar 2025) to 5.92, marking an increase of 2.14.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 3:14 am
| Metric | Mar 2016 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,382 | 1,343 | 1,456 | 1,500 | 1,447 | 2,167 | 2,710 | 3,275 | 3,692 | 3,862 |
| Expenses | 1,081 | 1,218 | 1,283 | 1,309 | 1,250 | 1,709 | 2,073 | 2,466 | 2,806 | 2,925 |
| Operating Profit | 301 | 125 | 172 | 192 | 197 | 458 | 637 | 809 | 886 | 937 |
| OPM % | 22% | 9% | 12% | 13% | 14% | 21% | 24% | 25% | 24% | 24% |
| Other Income | 45 | 49 | 50 | 44 | 31 | 39 | 49 | 75 | 29 | 28 |
| Interest | 14 | 28 | 38 | 57 | 73 | 86 | 86 | 84 | 74 | 61 |
| Depreciation | 70 | 86 | 102 | 115 | 123 | 130 | 150 | 173 | 194 | 192 |
| Profit before tax | 262 | 60 | 83 | 64 | 32 | 281 | 449 | 627 | 647 | 712 |
| Tax % | 35% | 45% | 38% | 43% | 11% | 30% | 27% | 24% | 26% | |
| Net Profit | 170 | 33 | 51 | 36 | 29 | 196 | 326 | 478 | 481 | 534 |
| EPS in Rs | 35.10 | 6.78 | 10.44 | 7.36 | 5.81 | 7.75 | 12.16 | 17.81 | 17.92 | 19.89 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 54.55% | -29.41% | -19.44% | 575.86% | 66.33% | 46.63% | 0.63% |
| Change in YoY Net Profit Growth (%) | 0.00% | -83.96% | 9.97% | 595.31% | -509.54% | -19.70% | -46.00% |
Global Health Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 7 years from 2018-2019 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 20% |
| 3 Years: | 19% |
| TTM: | 15% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 70% |
| 3 Years: | 38% |
| TTM: | 18% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | 24% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 14% |
| 3 Years: | 17% |
| Last Year: | 16% |
Last Updated: September 5, 2025, 3:36 pm
Balance Sheet
Last Updated: December 4, 2025, 2:57 am
| Month | Mar 2016 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 48 | 48 | 49 | 49 | 50 | 51 | 54 | 54 | 54 | 54 |
| Reserves | 976 | 1,136 | 1,246 | 1,300 | 1,333 | 1,565 | 2,375 | 2,852 | 3,333 | 3,654 |
| Borrowings | 165 | 456 | 787 | 929 | 931 | 1,109 | 1,122 | 802 | 718 | 945 |
| Other Liabilities | 295 | 343 | 347 | 388 | 380 | 421 | 547 | 572 | 662 | 757 |
| Total Liabilities | 1,485 | 1,984 | 2,430 | 2,666 | 2,694 | 3,146 | 4,097 | 4,280 | 4,766 | 5,410 |
| Fixed Assets | 914 | 1,094 | 1,194 | 1,703 | 1,616 | 1,776 | 2,050 | 2,236 | 2,514 | 3,199 |
| CWIP | 12 | 317 | 666 | 382 | 464 | 439 | 327 | 388 | 533 | 318 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 3 |
| Other Assets | 559 | 573 | 570 | 581 | 615 | 930 | 1,720 | 1,656 | 1,716 | 1,890 |
| Total Assets | 1,485 | 1,984 | 2,430 | 2,666 | 2,694 | 3,146 | 4,097 | 4,280 | 4,766 | 5,410 |
Below is a detailed analysis of the balance sheet data for Global Health Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 54.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 54.00 Cr..
- For Reserves, as of Sep 2025, the value is 3,654.00 Cr.. The value appears strong and on an upward trend. It has increased from 3,333.00 Cr. (Mar 2025) to 3,654.00 Cr., marking an increase of 321.00 Cr..
- For Borrowings, as of Sep 2025, the value is 945.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 718.00 Cr. (Mar 2025) to 945.00 Cr., marking an increase of 227.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 757.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 662.00 Cr. (Mar 2025) to 757.00 Cr., marking an increase of 95.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 5,410.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 4,766.00 Cr. (Mar 2025) to 5,410.00 Cr., marking an increase of 644.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 3,199.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,514.00 Cr. (Mar 2025) to 3,199.00 Cr., marking an increase of 685.00 Cr..
- For CWIP, as of Sep 2025, the value is 318.00 Cr.. The value appears to be declining and may need further review. It has decreased from 533.00 Cr. (Mar 2025) to 318.00 Cr., marking a decrease of 215.00 Cr..
- For Investments, as of Sep 2025, the value is 3.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 3.00 Cr..
- For Other Assets, as of Sep 2025, the value is 1,890.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,716.00 Cr. (Mar 2025) to 1,890.00 Cr., marking an increase of 174.00 Cr..
- For Total Assets, as of Sep 2025, the value is 5,410.00 Cr.. The value appears strong and on an upward trend. It has increased from 4,766.00 Cr. (Mar 2025) to 5,410.00 Cr., marking an increase of 644.00 Cr..
Notably, the Reserves (3,654.00 Cr.) exceed the Borrowings (945.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2016 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 136.00 | -331.00 | -615.00 | -737.00 | -734.00 | 457.00 | 636.00 | 7.00 | 168.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2016 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 20 | 41 | 41 | 36 | 34 | 30 | 26 | 24 | 29 |
| Inventory Days | 28 | 26 | 26 | 43 | 42 | 36 | 35 | 32 | 28 |
| Days Payable | 92 | 124 | 142 | 147 | 138 | 90 | 114 | 90 | 81 |
| Cash Conversion Cycle | -45 | -56 | -75 | -67 | -62 | -24 | -52 | -34 | -24 |
| Working Capital Days | -23 | -33 | -18 | -31 | -48 | -20 | -37 | -32 | -21 |
| ROCE % | 6% | 6% | 5% | 15% | 17% | 20% | 20% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 2.00 | 2.00 | 2.00 | 2.00 | 10.00 |
| Basic EPS (Rs.) | 17.92 | 17.80 | 12.58 | 7.78 | 1.15 |
| Diluted EPS (Rs.) | 17.92 | 17.80 | 12.57 | 7.77 | 1.14 |
| Cash EPS (Rs.) | 25.13 | 24.24 | 17.75 | 12.87 | 30.66 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 126.08 | 108.21 | 90.54 | 63.82 | 272.22 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 126.08 | 108.21 | 90.54 | 63.82 | 272.22 |
| Revenue From Operations / Share (Rs.) | 137.47 | 121.98 | 100.46 | 85.56 | 291.76 |
| PBDIT / Share (Rs.) | 35.60 | 32.54 | 25.25 | 19.34 | 44.94 |
| PBIT / Share (Rs.) | 28.39 | 26.11 | 19.66 | 14.22 | 20.09 |
| PBT / Share (Rs.) | 24.10 | 23.36 | 16.75 | 11.08 | 6.55 |
| Net Profit / Share (Rs.) | 17.92 | 17.80 | 12.16 | 7.75 | 5.81 |
| NP After MI And SOA / Share (Rs.) | 17.92 | 17.81 | 12.16 | 7.75 | 5.81 |
| PBDIT Margin (%) | 25.89 | 26.67 | 25.13 | 22.60 | 15.40 |
| PBIT Margin (%) | 20.64 | 21.40 | 19.56 | 16.61 | 6.88 |
| PBT Margin (%) | 17.52 | 19.14 | 16.67 | 12.94 | 2.24 |
| Net Profit Margin (%) | 13.03 | 14.59 | 12.10 | 9.05 | 1.99 |
| NP After MI And SOA Margin (%) | 13.03 | 14.60 | 12.10 | 9.05 | 1.99 |
| Return on Networth / Equity (%) | 14.21 | 16.45 | 13.42 | 12.14 | 2.13 |
| Return on Capital Employeed (%) | 18.38 | 19.01 | 14.87 | 13.20 | 4.35 |
| Return On Assets (%) | 10.10 | 11.11 | 7.92 | 6.23 | 1.06 |
| Long Term Debt / Equity (X) | 0.07 | 0.09 | 0.30 | 0.47 | 0.42 |
| Total Debt / Equity (X) | 0.09 | 0.14 | 0.34 | 0.51 | 0.47 |
| Asset Turnover Ratio (%) | 0.81 | 0.77 | 0.61 | 0.69 | 0.52 |
| Current Ratio (X) | 2.48 | 2.44 | 2.76 | 1.94 | 1.24 |
| Quick Ratio (X) | 2.37 | 2.33 | 2.65 | 1.81 | 1.14 |
| Inventory Turnover Ratio (X) | 55.11 | 10.81 | 9.00 | 10.58 | 8.41 |
| Interest Coverage Ratio (X) | 14.65 | 11.82 | 8.69 | 6.16 | 3.32 |
| Interest Coverage Ratio (Post Tax) (X) | 9.14 | 7.47 | 5.18 | 3.47 | 1.43 |
| Enterprise Value (Cr.) | 31388.50 | 34786.03 | 13675.20 | 0.00 | 0.00 |
| EV / Net Operating Revenue (X) | 8.50 | 10.62 | 5.08 | 0.00 | 0.00 |
| EV / EBITDA (X) | 32.83 | 39.81 | 20.20 | 0.00 | 0.00 |
| MarketCap / Net Operating Revenue (X) | 8.72 | 10.85 | 5.24 | 0.00 | 0.00 |
| Price / BV (X) | 9.50 | 12.23 | 5.81 | 0.00 | 0.00 |
| Price / Net Operating Revenue (X) | 8.72 | 10.85 | 5.24 | 0.00 | 0.00 |
| EarningsYield | 0.01 | 0.01 | 0.02 | 0.00 | 0.00 |
After reviewing the key financial ratios for Global Health Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 2.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 17.92. This value is within the healthy range. It has increased from 17.80 (Mar 24) to 17.92, marking an increase of 0.12.
- For Diluted EPS (Rs.), as of Mar 25, the value is 17.92. This value is within the healthy range. It has increased from 17.80 (Mar 24) to 17.92, marking an increase of 0.12.
- For Cash EPS (Rs.), as of Mar 25, the value is 25.13. This value is within the healthy range. It has increased from 24.24 (Mar 24) to 25.13, marking an increase of 0.89.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 126.08. It has increased from 108.21 (Mar 24) to 126.08, marking an increase of 17.87.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 126.08. It has increased from 108.21 (Mar 24) to 126.08, marking an increase of 17.87.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 137.47. It has increased from 121.98 (Mar 24) to 137.47, marking an increase of 15.49.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 35.60. This value is within the healthy range. It has increased from 32.54 (Mar 24) to 35.60, marking an increase of 3.06.
- For PBIT / Share (Rs.), as of Mar 25, the value is 28.39. This value is within the healthy range. It has increased from 26.11 (Mar 24) to 28.39, marking an increase of 2.28.
- For PBT / Share (Rs.), as of Mar 25, the value is 24.10. This value is within the healthy range. It has increased from 23.36 (Mar 24) to 24.10, marking an increase of 0.74.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 17.92. This value is within the healthy range. It has increased from 17.80 (Mar 24) to 17.92, marking an increase of 0.12.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 17.92. This value is within the healthy range. It has increased from 17.81 (Mar 24) to 17.92, marking an increase of 0.11.
- For PBDIT Margin (%), as of Mar 25, the value is 25.89. This value is within the healthy range. It has decreased from 26.67 (Mar 24) to 25.89, marking a decrease of 0.78.
- For PBIT Margin (%), as of Mar 25, the value is 20.64. This value exceeds the healthy maximum of 20. It has decreased from 21.40 (Mar 24) to 20.64, marking a decrease of 0.76.
- For PBT Margin (%), as of Mar 25, the value is 17.52. This value is within the healthy range. It has decreased from 19.14 (Mar 24) to 17.52, marking a decrease of 1.62.
- For Net Profit Margin (%), as of Mar 25, the value is 13.03. This value exceeds the healthy maximum of 10. It has decreased from 14.59 (Mar 24) to 13.03, marking a decrease of 1.56.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 13.03. This value is within the healthy range. It has decreased from 14.60 (Mar 24) to 13.03, marking a decrease of 1.57.
- For Return on Networth / Equity (%), as of Mar 25, the value is 14.21. This value is below the healthy minimum of 15. It has decreased from 16.45 (Mar 24) to 14.21, marking a decrease of 2.24.
- For Return on Capital Employeed (%), as of Mar 25, the value is 18.38. This value is within the healthy range. It has decreased from 19.01 (Mar 24) to 18.38, marking a decrease of 0.63.
- For Return On Assets (%), as of Mar 25, the value is 10.10. This value is within the healthy range. It has decreased from 11.11 (Mar 24) to 10.10, marking a decrease of 1.01.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.07. This value is below the healthy minimum of 0.2. It has decreased from 0.09 (Mar 24) to 0.07, marking a decrease of 0.02.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.09. This value is within the healthy range. It has decreased from 0.14 (Mar 24) to 0.09, marking a decrease of 0.05.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.81. It has increased from 0.77 (Mar 24) to 0.81, marking an increase of 0.04.
- For Current Ratio (X), as of Mar 25, the value is 2.48. This value is within the healthy range. It has increased from 2.44 (Mar 24) to 2.48, marking an increase of 0.04.
- For Quick Ratio (X), as of Mar 25, the value is 2.37. This value exceeds the healthy maximum of 2. It has increased from 2.33 (Mar 24) to 2.37, marking an increase of 0.04.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 55.11. This value exceeds the healthy maximum of 8. It has increased from 10.81 (Mar 24) to 55.11, marking an increase of 44.30.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 14.65. This value is within the healthy range. It has increased from 11.82 (Mar 24) to 14.65, marking an increase of 2.83.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 9.14. This value is within the healthy range. It has increased from 7.47 (Mar 24) to 9.14, marking an increase of 1.67.
- For Enterprise Value (Cr.), as of Mar 25, the value is 31,388.50. It has decreased from 34,786.03 (Mar 24) to 31,388.50, marking a decrease of 3,397.53.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 8.50. This value exceeds the healthy maximum of 3. It has decreased from 10.62 (Mar 24) to 8.50, marking a decrease of 2.12.
- For EV / EBITDA (X), as of Mar 25, the value is 32.83. This value exceeds the healthy maximum of 15. It has decreased from 39.81 (Mar 24) to 32.83, marking a decrease of 6.98.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 8.72. This value exceeds the healthy maximum of 3. It has decreased from 10.85 (Mar 24) to 8.72, marking a decrease of 2.13.
- For Price / BV (X), as of Mar 25, the value is 9.50. This value exceeds the healthy maximum of 3. It has decreased from 12.23 (Mar 24) to 9.50, marking a decrease of 2.73.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 8.72. This value exceeds the healthy maximum of 3. It has decreased from 10.85 (Mar 24) to 8.72, marking a decrease of 2.13.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Global Health Ltd:
- Net Profit Margin: 13.03%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 18.38% (Industry Average ROCE: 15.8%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 14.21% (Industry Average ROE: 8.84%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 9.14
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 2.37
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 51.8 (Industry average Stock P/E: 50.11)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.09
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 13.03%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Non-Banking Financial Company (NBFC) | Sir RNM House, Kolkata West Bengal 700001 | gcmil1995@gmail.com http://www.globalcapitalmarketandinfraltd.co.in |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Inder Chand Baid | Chairman & Managing Director |
| Mr. Mahavir Prasad Saraswat | Independent Director |
| Mr. Urmi Bose | Independent Director |
| Ms. Akshaya Suved Chavan | Independent Director |
| Mr. Manish Baid | Non Executive Director |
FAQ
What is the intrinsic value of Global Health Ltd?
Global Health Ltd's intrinsic value (as of 13 December 2025) is 943.97 which is 18.06% lower the current market price of 1,152.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 30,975 Cr. market cap, FY2025-2026 high/low of 1,456/995, reserves of ₹3,654 Cr, and liabilities of 5,410 Cr.
What is the Market Cap of Global Health Ltd?
The Market Cap of Global Health Ltd is 30,975 Cr..
What is the current Stock Price of Global Health Ltd as on 13 December 2025?
The current stock price of Global Health Ltd as on 13 December 2025 is 1,152.
What is the High / Low of Global Health Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Global Health Ltd stocks is 1,456/995.
What is the Stock P/E of Global Health Ltd?
The Stock P/E of Global Health Ltd is 51.8.
What is the Book Value of Global Health Ltd?
The Book Value of Global Health Ltd is 138.
What is the Dividend Yield of Global Health Ltd?
The Dividend Yield of Global Health Ltd is 0.04 %.
What is the ROCE of Global Health Ltd?
The ROCE of Global Health Ltd is 19.7 %.
What is the ROE of Global Health Ltd?
The ROE of Global Health Ltd is 16.5 %.
What is the Face Value of Global Health Ltd?
The Face Value of Global Health Ltd is 2.00.